Navigation Links
Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians
Date:8/19/2008

MUMBAI, India and BALTIMORE, Aug. 19 /PRNewswire/ -- Lupin Ltd. announced today that the Company has entered into a multi-year promotion and marketing agreement for the AeroChamber Plus(R) line of products with Forest Laboratories, Inc. Under the terms of the agreement, Lupin Pharmaceuticals, Inc., USA, will use its 50 person sales force to promote the product to pediatricians.

AeroChamber Plus(R) is a Valved Holding Chamber (VHC) device that is used with metered dose inhalers to improve the delivery of medication to the lungs in the treatment of asthma and COPD. AeroChamber Plus(R) also reduces the deposition of medication in the mouth and throat and makes metered dose inhalers easier for patients to use by reducing the need to coordinate actuation of the inhaler with inhalation. AeroChamber Plus(R) is the most widely prescribed holding chamber in the United States and has been used by millions of patients since its introduction. Approximately two thirds of AeroChamber Plus(R) Valved Holding Chamber prescriptions (IMS 2007 data) are written by pediatricians.

"We are happy to strike this alliance with Forest. While the AeroChamber Plus(R) brand has a strong position in the Valved Holding Chamber market, we believe that this marketing alliance presents a significant opportunity for further growth of the franchise for Forest, resulting in value for both companies," said Vinita Gupta, President, LPI.

This agreement with Forest Laboratories, Inc. reflects Lupin's commitment to bring value additions to the US market to improve the overall health of the patient population. This alliance will also extend Lupin's presence in the respiratory segment and help strengthen its franchise with pediatricians.

About Lupin

Lupin Pharmaceuticals, Inc., headquartered in Baltimore, Maryland, is the wholly owned U.S. subsidiary of Mumbai based Lupin Limited, a leading Indian Pharmaceutical company. Lupin Limited develops, manufactures and markets a wide range of quality, affordable generic and branded generic formulations and APIs for the developed and the developing markets of the world. Twelve of Lupin's facilities have been inspected and approved by the U.S. Food & Drug Administration.

For the year ended March 2008, the Lupin's consolidated Revenues and Profit after Tax were Rs. 27730 million (USD 660.23 million) and Rs. 4083 million (USD 102 million) respectively.

The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs. Currently positioned amongst the top five pharmaceutical companies of India, the Company is committed to achieve sustainable earnings and growth for all its stakeholders.

AeroChamber Plus(R) is a registered trademark of Trudell-Monaghan.

For More Information:

Lupin Pharmaceuticals, Inc.

Contact: Atul Gokhale

General Manager - Marketing

410-576-2000

Web site: http://www.lupinpharmaceuticals.com.


'/>"/>
SOURCE Lupin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
2. Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for Suprax(R) 400 mg Tablets in the U.S.
3. Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets
4. Lupin Launches Ramipril Capsules
5. Lupin Receives USFDA Approval for Topiramate Tablets
6. Older Patients Less Likely to Be Taken to Trauma Centers
7. VA Opening Rural Health Resource Centers
8. AUDIO from Medialink and Pfizer: Community Health Centers Celebrated for Making Quality Care Available to Uninsured Americans
9. Nighttime Care Centers Introduce Mini C-Arm Mobile X-Ray Technology to Anne Arundel County
10. IPC The Hospitalist Company Enters Ohio and Pennsylvania Markets
11. Bederra Corp.s Lumar Imaging Division Enters Into Joint Venture With Basic Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: